The development and approval of therapeutic antibodies and antibody-related drugs have grown significantly in the past decade. The success of fully human antibodies in the clinic proved that genetically engineered mouse models that produce human antibodies can significantly accelerate therapeutic antibody discovery. Antibodies generated from these novel mouse models have favorable properties such as low immunogenicity, high diversity, affinity and developability.

In this live broadcast, Mingkun Zhang, Vice President of NeoMab Bio will share the following insights on latest technology in antibody drug discovery:

• Technology Improvement in Antibody Drug Discovery

• The Fully Human Antibody Discovery Platform

• Strategies to Enhance Immune Response: Breaking Immune Tolerance

• Solutions to Accelerate The Fully Human Antibody Discovery

Date:

Thursday, November 21, 2024

8:00 AM PST | 10:00 AM CST | 11:00 AM EST | 5:00 PM CET